Pilot Study: Creating Antibody-Drug Linkages

试点研究：建立抗体-药物联系

• 批准号: 446723-2013
• 负责人: Kluger, Ronald
• 金额: $ 1.82万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=536490
• 关键词: Pilot; Study; Creating; Antibody; Drug

AvidBiologics is interested in developing products that direct anti-cancer drugs specifically to target cancer cells in tumors. In doing so, they have acquired a collection of antibody proteins that have been shown to bind to malignant tumors. The proposed research at the University of Toronto will develop ways to attach drugs chemically to those antibodies, so that the drug can be guided specifically to the desired site of action. The project involves designing the chemicals to be used as connecting reagents, producing the desired chemicals, and then developing a process for attaching anti-cancer drugs. The resulting drug-linked reagents will then be tested for their ability to react specifically with the cell-targeting antibodies and the successfully produced materials will be evaluated by AvidBiologics. This is an introductory study to determine the feasibility of the approach and to establish a collaborative effort should the results obtained justify further work.

AvidBiologics有兴趣开发直接抗癌药物专门针对肿瘤中癌细胞的产品。在这样做的过程中，他们已经获得了一系列抗体蛋白，这些抗体蛋白已被证明与恶性肿瘤结合。多伦多大学拟议的研究将开发出将药物化学附着在那些抗体上的方法，这样药物就可以被特异性地引导到所需的作用部位。该项目涉及设计用作连接试剂的化学品，生产所需的化学品，然后开发一种连接抗癌药物的过程。然后将测试所得药物连接试剂与细胞靶向抗体特异性反应的能力，并由AvidBiologics评价成功生产的材料。这是一项介绍性研究，目的是确定这一方法的可行性，并在取得的结果证明有必要进一步开展工作时开展合作。